Loading...
NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK
BACKGROUND: The objective was to evaluate the cost-effectiveness of NEPA, an oral fixed combination netupitant (NETU, 300 mg) and palonosetron (PA, 0.5 mg) compared with aprepitant and palonosetron (APPA) or palonosetron (PA) alone, to prevent chemotherapy-induced nausea and vomiting (CINV) in patie...
Na minha lista:
| Udgivet i: | Drugs Context |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Just Medical Media Limited
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5378057/ https://ncbi.nlm.nih.gov/pubmed/28392826 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212298 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|